anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
The invention discloses an instant effervescent tablet, a preparation method and application thereof, and relates to the technical field of effervescent tablets. The instant effervescent tablet comprises the following raw materials in percentage by weight: 15-60% of effervescent agent, 25-75% of microcrystalline cellulose, 0-4% of sweetener, 0-20% of efficacy active substance, 0-5% of lubricant and 0-10% of essence, wherein the effervescent agent comprises acidic effervescent agent and alkaline effervescent agent. By controlling the addition of microcrystalline cellulose in an amount of more than 25%, the ability to contribute to the promotion of disintegration can be qualitatively changed. Thereby greatly shortening the disintegration time of the effervescent tablet, reducing the waiting time of consumers and being more convenient to use. The effervescent tablet provided by the invention can be well compatible with efficacy active substances, and the activity of the effervescent tablet is kept. The effervescent tablet provided by the invention has more stable characteristics than the conventional effervescent tablet, and reduces the requirements on air humidity and raw material moisture in the processing process.
Text messaging frame = importance of vaccines. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
Trained medical students will deliver the intervention and will be conducted in the specific classrooms of enrolled schools. The school students will be taught how to use the SmokerFace App from the Education Against Tobacco (EAT) program (26) with parental supervision at home. Medical Students will send the links to download the app from the App Store (iOS) and Play Store (Android), along with an explanation of how to install and use the app.
Sleep genetics is an intriguing, as yet less understood, understudied, emerging area of biological and medical discipline. A generalist may not be aware of the current status of the field given the variety of journals that have published studies on the genetics of sleep and the circadian clock over the years. For researchers venturing into this fascinating area, this review thus includes fundamental features of circadian rhythm and genetic variables impacting sleep-wake cycles. Sleep/wake pathway medication exposure and susceptibility are influenced by genetic variations, and the responsiveness of sleep-related medicines is influenced by several functional polymorphisms. This review highlights the features of the circadian timing system and then a genetic perspective on wakefulness and sleep, as well as the relationship between sleep genetics and sleep disorders. Neurotransmission genes, as well as circadian and sleep/wake receptors, exhibit functional variability. Experiments on animals and humans have shown that these genetic variants impact clock systems, signaling pathways, nature, amount, duration, type, intensity, quality, and quantity of sleep. In this regard, the overview covers research on sleep genetics, the genomic properties of several popular model species used in sleep studies, homologs of mammalian genes, sleep disorders, and related genes. In addition, the study includes a brief discussion of sleep, narcolepsy, and restless legs syndrome from the viewpoint of a model organism. It is suggested that the understanding of genetic clues on sleep function and sleep disorders may, in future, result in an evidence-based, personalized treatment of sleep disorders.
The retinal pigment epithelium (RPE) forms the outer blood-retinal barrier between photoreceptor cells and choroidal blood vessels. Photoreceptor cells are vitally and functionally dependent on the RPE. The conversion of blood glucose to ATP, synthesis of proteins in the visual cycle and removal of metabolic waste takes place in the RPE. For these important processes, various peptide growth factors and their receptors are synthesized in the RPE. More than 260 genes in the RPE are responsible for the production of these peptide fragments. Mutations in any of these genes as well as ischemic, physical or chemical RPE damage causes retinal degeneration. Retinal degeneration may be inherited, such as in retinitis pigmentosa (RP), Stargardt's disease, choroideremia, Best vitelliform dystrophy and Bietti's crystalline dystrophy. Retinal degeneration may also be acquired through genetic mechanisms, such as age-releated macular degeneration. In retinal degeneration, there is a developing loss of RPE and photoreceptors, regardless of the underlying cause.

Umbilical cord Wharton's jelly derived mesenchymal stem cells (WJ-MSCs) have significant paracrine and immunomodulatory properties. WJ-MSCs secrete trophic factors that stimulate RPE or secrete trophic factors that are similar to those produced by RPE. In studies using animal models, WJ-MSCs have been found to be effective in stopping the progression of retinal degeneration and for rescuing photoreceptors in the dormant phase. WJ-MSCs are hypoimmunogenic and have significant immunomodulatory properties. WJ-MSCs have been shown to suppress chronic inflammation and prevent apoptosis in animal models of neurodegenerative and ischemic retinal disorders. WJ-MSCs also stimulate progenitor cells in the retina and elicit self-repair mechanisms.

The aim of this preliminary clinical study is to investigate the efﬁcacy of deep sub-tenon injected WJ-MSCs as a stem cell treatment modality for the management of retinitis pigmentosa, which creates outer retinal degeneration. These functional and structural effects were investigated using microperimetry, electrophysiology and spectral domain optical coherence tomography (SD-OCT). To the best of our knowledge, this is the first prospective clinical study that utilizes a large number of RP cases, and cases that are in phase-3.
The present invention discloses a peanut and aloe cake and a preparation technology thereof. The peanut and aloe cake is a rice food with the efficiency of reinforcing the spleen and the stomach and loosening the bowel to relieve constipation. The preparation method of the peanut and aloe cake is simple, and the efficiency of each component is reserved. The peanut and aloe cake is prepared from the raw materials by the weight percentage: 50 to 70 wt% of glutinous rice, 10 to 25 wt% of white sugar, 10 to 20 wt% of peanut kernel and 5 to 15 wt% of aloe mesophyll. The main preparation technology comprises the following steps: material preparation, material mixing, forming, cake cutting, cake baking, packaging and warehousing. The peanut and aloe cake has rich nutrition and convenient taking, is especially suitable for the old, the weak and the persons with intestine dryness and constipation to take, and has the function of adjuvant therapy.
BACKGROUND AND OBJECTIVES: Considering the significant prevalence of ileus after abdominal surgery and the beneficial effects of Cuminum cyminum in digestive problems, this study aimed to examine whether Cuminum cyminum has any effect on the return of bowel motility after abdominal surgery.
MATERIALS AND METHODS: In this triple-blind clinical trial study, 74 patients undergoing abdominal surgery were assigned to the intervention and control groups using minimization methods. The patients in the intervention group consumed 250 mg capsules containing Cuminum cyminum extract 4 h after the surgery and another dose of the drug 1 h afterward. The patients in the control group consumed a 250 mg capsule containing starch as a placebo at hours similar to those in the intervention group. The instruments used to collect the data were a demographic questionnaire and a researcher-made checklist to assess bowel habits. The data were analyzed using SPSS-22 software.
RESULTS: The average time of gas passing in the intervention and control groups was 9.03 ± 3.41 and 11.72 ± 4.21 h, respectively. The defecation times in the intervention and control groups were 16.97 ± 5.02 and 26 ± 9.87 h, showing a significant difference between the two groups as indicated by the independent samples T-test (P > 0.001). Furthermore, abdominal pain, abdominal bloating, nausea, and vomiting were significantly less frequent in the intervention group compared to the control group as confirmed by Fisher's exact test (P > 0.001).
CONCLUSION: According to the results, the consumption of Cuminum cyminum after abdominal surgery helps to reduce the time of gas passing, defecation, and the return of bowel motility. However, additional studies need to address the effectiveness of Cuminum cyminum by changing the time and duration of its use.
Single-arm, open-label study. Intervention consists of intralesional injection of nonavalent human papillomavirus vaccine at 0 and 4 weeks.
The present invention discloses a new approach to the therapy of cancer in humans based on the administration of lymphokine activated killer (LAK) cells and interleukin-2 (IL-2). Twelve patients with metastatic cancer who had failed standard available therapy were treated. LAK cells were generated from peripheral blood mononuclear cells obtained at multiple leukaphereses and incubated in the recombinant-derived lymphokine, IL-2. Following three to four days of incubation in IL-2, the resulting LAK cells were capable of lysing fresh tumor cells but not normal cells. These LAK cells were reinfused into the autologous patient, along with the intravenous administration of recombinant IL-2 every 8 hours. Patients received up to 90 doses of IL-2 and from 2.8 to 12.6×10 10  activated cells from up to 14 sequential leukaphereses. Six patients showed objective regression of established cancer.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of displaying excellent effect on proliferative organ diseases such as carcinoma, sarcoma and myoma by making the medicine contain an erythropoietin antagonist as an active ingredient. SOLUTION: This medicine contains an erythropoietin antagonist, preferably an antierythropoietin antibody or an erythropoietin receptor protein (preferably in particular a soluble erythropoietin receptor protein) as an active ingredient. It is preferable that this medicine is topically and directly administrated to cancered or tumoral tissues or organs in forms of liquids and solutions, e.g., injection and the like. If tumor focuses exist in topical parts, it is preferable to administrate to the cancer having a size of little finger head (about 1g) in an amount of about 30-50μg per one administration. This process is useful for treatment and reformation of every cancerous ulters, e.g. uterine cancer, uterine myoma and skin carcinoma.
Excess of low density lipoproteins, high blood pressure, obesity, excess of blood sugar levels, smoking and sedentary life style are the known modifiable risk factors causing cardiovascular disease specifically Coronary disease. There can be some other substances which can additionally affect the human cardiac physiology as well i.e. high levels of Homocysteine molecule in the blood. The adverse effects of this component on multiple system of human body are evidenced in the literature since 1962 involving Nervous system, brain, Renal system, Liver functioning, Venus system and endothelial system and are still under debate. This biochemical agent has a strong relevance with the physiology of cardiovascular system and causes disturbance in the arterial supply of the heart in young population.

Homocysteine has been under a lot of discussion it is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues. Homocysteine has a strong relation with the diseases involving hardening of arteries and blood clots related vascular problems.
Troponin T1 (TNNT1) plays a crucial role in muscle contraction but its role in cancer, particularly in kidney renal clear cell carcinoma (KIRC), is not well-understood. This study explores the expression, clinical significance and biological functions of TNNT1 in various cancers, with an emphasis on its involvement in KIRC. We analysed TNNT1 expression in cancers using databases like TCGA and GTEx, assessing its prognostic value, mutation patterns, methylation status and functional implications. The study also examined TNNT1's effect on the tumour microenvironment and drug sensitivity in KIRC, complemented by in vitro TNNT1 knockdown experiments in KIRC cells. TNNT1 is overexpressed in several cancers and linked to adverse outcomes, showing frequent upregulation mutations and abnormal methylation. Functionally, TNNT1 connects to muscle and cancer pathways, affects immune infiltration and drug responses, and its overexpression in KIRC is associated with advanced disease and reduced survival. Knocking down TNNT1 curbed KIRC cell growth. TNNT1's aberrant expression plays a significant role in tumorigenesis and immune modulation, highlighting its value as a prognostic biomarker and a potential therapeutic target in KIRC and other cancers. Further studies are essential to understand TNNT1's oncogenic mechanisms in KIRC.
1,256,276. Dentifrices. INDIANA UNIVERSITY FOUNDATION. 25 March, 1969, No. 15502/69. Heading A5B. [Also in Division Cl] Oral compositions for dental caries prophylaxis e.g. dentifrices, mouthwashes, prophylaxis pastes and aqueous topical solutions comprise 0.01-50% by weight of indium fluorogerminate In 2 (GeFo) 3 . Compositions for frequent use, e.g. dentifrices contain lower amounts of the compound than those used less frequently. Suitable amounts are 0.1-1.0% by weight for dentifrices and mouthwashes; 5-30% by weight for prophylaxis pastes and 5-40% for aqueous topical solutions. Dentifrice compositions and prophylactic pastes also comprise 20-95% of fluoride compatible cleaning and polishing agents e.g. calcium pyrophosphate, sodium metaphosphate, calcium carbonate and melamine formaldehyde resins. Toothpaste compositions also comprise conventional thickening and sudsing agents, a binder and some humectant material. Prophylactic pastes containing indium fluorogerminate also contain the usual additives e.g. an abrasive.
Systems, methods, computer storage media, and user interfaces are provided for associating patients and medical devices with a mobile device via Bluetooth. A signal associated with a patient communicated via a Bluetooth personal area network is received. The patient associated with the signal is recognized. An association request to associate the patient to a medical device is initiated and communicated to a mobile device associated with a clinician when the mobile device is in range. Once the clinician has provided an indication that the association request is approved, the patient is associated to the medical device. Data may be automatically logged in a shift log associated with the clinician while the mobile device is communicating with the medical device or the signal associated with the patient via the Bluetooth personal area network.
Research has shown that people with an intellectual disability have higher rates of certain preventable health conditions and a higher rate of avoidable mortality relative to the general population. With respect to health behaviours, they also have lower levels of physical activity and poorer nutrition. Despite the increased health needs, this population cohort is less likely to have the opportunity to participate in health promotion programs. The interventions that have been delivered are programmatic and individual in focus and have lacked a broader ecological and settings focus, which makes them very difficult to scale. Health promotion programs designed for the general population, such as lifestyle campaigns, rarely reach people with an intellectual disability. This increases the importance of ensuring that the settings in which they live and engage with are as health promoting as possible. Interventions have been particularly absent in the workplace for people with an intellectual disability. This paper highlights gaps in a settings-and-systems-based approach to promoting the health and wellbeing of people with an intellectual disability, particularly with respect to workplace health promotion. The paper concludes with recommendations for a systems approach that integrates approaches across multiple settings to better promote the health of this population cohort.
A method is disclosed for producing soft, gentle waves in negroid hair without use of curlers. Negroid hair, in the naturally kinky state is first treated with hair straightening chemicals to establish a standard reference time for carrying out a hair straightening treatment. With this reference time determined, it is then possible to treat this hair, or other similar hair in accordance with this process. 
     An untreated negroid hair, in the naturally kinky state is wet thoroughly and hair straightening chemicals applied thereto and allowed to set for a period of 10-15 minutes, corresponding to about 70-90% of the time of exposure of the hair to the chemicals required for straightening the hair. The precise time allowed for the treatment depends on the coarseness of the hair. The hair is combed out and stretched in sections during the time of exposure to the hair-straightening chemicals. Next, the hair is shampooed using a shampoo containing chemicals for neutralizing the hair straightener. The hair is then rinsed and set and a hair softener applied. The hair is then allowed to dry without heat or blowing. The method produces soft gentle waves without use of curlers and is effective in curling hair in periods of time as short as 25-30 minutes.
Different antiviral treatments for chronic hepatitis B (CHB) have been known to have different metabolic effects. This study aimed to reveal whether tenofovir alafenamide (TAF)-induced dyslipidemia and its associated outcomes are significant. This study utilized 15-year historical cohort including patients with CHB in Korea and consisted of two parts: the single-antiviral and switch-antiviral cohorts. In the single-antiviral cohort, patients were divided into four groups (entecavir [ETV]-only, tenofovir disoproxil fumarate [TDF]-only, TAF-only, and non-antiviral). Propensity score matching (PSM) and linear regression model were sequentially applied to compare metabolic profiles and estimated atherosclerotic cardiovascular disease (ASCVD) risks longitudinally. In the switch-antiviral cohort, pairwise analyses were conducted in patients who switched NAs to TAF or from TAF. In the single-antiviral cohort, body weight and statin use showed significant differences between groups before PSM, but well-balanced after PSM. Changes in total cholesterol were significantly different between groups (-2.57 mg/dL/year in the TDF-only group and +2.88 mg/dL/year in the TAF-only group; p = 0.002 and p = 0.02, respectively). In the TDF-only group, HDL cholesterol decreased as well (-0.55 mg/dL/year; p < 0.001). The TAF-only group had the greatest increase in ASCVD risk, followed by the TDF-only group and the non-antiviral group. In the switch-antiviral cohort, patients who switched from TDF to TAF had a higher total cholesterol after switching (+9.4 mg/dL/year) than before switching (-1.0 mg/dL/year; p = 0.047). Sensitivity analysis on data with an observation period set to a maximum of 3 years for NA treatment showed consistent results on total cholesterol (-2.96 mg/dL/year in the TDF-only group and +3.09 mg/dL/year in the TAF-only group; p = 0.001 and p = 0.005, respectively). Another sensitivity analysis conducted on statin-treated patients revealed no significant change in cholesterol and ASCVD risk. TAF was associated with increased total cholesterol, whereas TDF was associated with decreased total and HDL cholesterol. Both TAF and TDF were associated with increased ASCVD risks, and statin use might mitigate these risks.
In the SBT group, the patients underwent a 1 hr SBT with inspiratory PS of 7 cmH2O with other settings remaining constant (FiO2, PEEP, trigger sensitivity). The patients who tolerated the SBT underwent immediate extubation.
AIMS: Reverse ventricular remodelling, defined as a decrease in left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the underlying pathophysiological mechanisms remain unclear.
METHODS AND RESULTS: We evaluated paired core-lab assessed echocardiograms and measurements of 92 biomarkers at baseline and 8 months thereafter in 419 participants with HFrEF. Reverse ventricular remodelling was defined as a >5% LVEF increase or >15% LVESVI relative decrease between baseline and 8 months. We evaluated the association between baseline biomarkers and their changes with reverse ventricular remodelling in the prospectively randomized controlled VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial. Of 419 patients (median age 66 [interquartile range 57-74] years, 27.4% women), 206 (49.2%) had reverse ventricular remodelling (either a 5% LVEF increase or a 15% LVESVI decrease). There were no differences in baseline biomarker concentrations between patients with versus those without reverse ventricular remodelling on follow-up. However, in patients with reverse ventricular remodelling there were significant decreases in biomarkers relating to inflammation and cardiac metabolism; particularly the tumour necrosis factor superfamily member 13B (ratio 0.82, 95% confidence interval [CI] 0.77-0.88), growth differentiation factor-15 (ratio 0.74, 95% CI 0.66-0.84), and insulin-like growth factor binding protein 7 (ratio 0.80, 95% CI 0.73-0.88).
CONCLUSIONS: Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism.
BACKGROUND: Primary percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) may reduce the risk of subsequent cardiovascular events but remains challenging. The study aim was to evaluate the clinical characteristics and long-term outcomes of patients undergoing primary PCI for STEMI with CS.
METHODS: We conducted an observational cohort study of patients with STEMI who underwent primary PCI between April 2004 and December 2017 at Juntendo University Shizuoka Hospital. The primary outcome was cardiovascular death (CVD) during the median 3-year follow-up. We performed a landmark analysis for the incidence of CVD from 0 day to 1 year and from 1 to 10 years.
RESULTS: Among the 1758 STEMI patients in the cohort, 212 (12.1 %) patients with CS showed significantly higher 30-day CVD rate on admission than those without (26.4 % vs 2.9 %). Landmark Kaplan-Meier analysis showed that CVD from day 0 to year 1 was significantly higher in the patients with CS (log-rank p < 0.0001). Multivariate Cox regression analysis showed that CS was significantly associated with higher cardiovascular mortality (adjusted hazard ratio, 11.8; 95%confidence intervals, 7.78-18.1; p < 0.0001), but the mortality rates from 1 to 10 years were comparable (log-rank p = 0.68).
CONCLUSION: The cardiovascular 1-year mortality rate for patients with STEMI was higher for those with CS on admission than without, but the mortality rates of >1 year were comparable. Surviving the early phase is essential for patients with STEMI and CS to improve long-term outcomes.